



## PRESS RELEASE

*This information was submitted for disclosure on 27 April 2018 at 08.45 (cet).*

## **Presentation of Probi's Q1 report 2018**

### **Probi's report for the first quarter 2018 will be published on Wednesday, 2 May at 8.00 a.m. CET**

In conjunction with this, analysts, investors and media are invited to an audiocast telephone conference on the same day at 10.00 a.m., where CFO Jörn Andreas will present and comment on the report. The presentation and presentation material can be obtained via [www.probi.com](http://www.probi.com) or <https://tv.streamfabriken.com/probi-q1-2018>

The presentation can also be followed via a telephone conference on the following telephone number:

Sweden: +46 8 50 55 64 53

UK: +44 20 30 08 98 10

US: +1 85 58 31 59 47

After the presentation, conference participants will be able to ask questions. Questions can also be asked via the audiocast.

An on-demand version of the presentation will be available at the address given above following the presentation.

### **FOR FURTHER INFORMATION, CONTACT:**

Jörn Andreas, CFO, Probi, tel +46 46 286 89 41, e-mail: [jorn.andreas@probi.com](mailto:jorn.andreas@probi.com)

### **ABOUT PROBI**

*Probi AB is a Swedish publicly traded bioengineering company. The vision of Probi is to help people live healthier lives by delivering effective and well-documented probiotics, with proven health benefits based on scientific research. Founded by scientists in Sweden in 1991, Probi is a multinational company with four sites, active in more than 40 markets around the world and holding over 400 patents worldwide. In 2017, Probi had net sales of MSEK 612. The Probi share is listed on Nasdaq Stockholm, Mid Cap. Probi has about 5,000 shareholders. Read more at [www.probi.com](http://www.probi.com)*